ARHGAP28 | Rho GTPase activating protein 28 | | | | | | Tissue enhanced |
ARHGAP6 | Rho GTPase activating protein 6 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ARHGDIG | Rho GDP dissociation inhibitor (GDI) gamma | | | | | | Tissue enhanced |
ARSF | Arylsulfatase F | Predicted membrane proteins
| | | | | Tissue enhanced |
ASB9 | Ankyrin repeat and SOCS box containing 9 | | | | | | Tissue enhanced |
ASPA | Aspartoacylase | Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
ASPHD1 | Aspartate beta-hydroxylase domain containing 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
ASRGL1 | Asparaginase like 1 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
ASS1 | Argininosuccinate synthase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
ATP2B2 | ATPase, Ca++ transporting, plasma membrane 2 | Enzymes Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ATP6V1B1 | ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 | Disease related genes
| | | | | Tissue enhanced |
ATP7B | ATPase, Cu++ transporting, beta polypeptide | Cancer-related genes Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
AUNIP | Aurora kinase A and ninein interacting protein | | | | | | Tissue enhanced |
AZGP1 | Alpha-2-glycoprotein 1, zinc-binding | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
B3GALT5 | UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 | Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT1 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT3 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT7 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 | Predicted secreted proteins
| | | | | Tissue enhanced |
B4GALNT2 | Beta-1,4-N-acetyl-galactosaminyl transferase 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
B4GALNT3 | Beta-1,4-N-acetyl-galactosaminyl transferase 3 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
B4GALNT4 | Beta-1,4-N-acetyl-galactosaminyl transferase 4 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
BAG2 | BCL2-associated athanogene 2 | Plasma proteins
| | | | | Tissue enhanced |
BANK1 | B-cell scaffold protein with ankyrin repeats 1 | Disease related genes
| | | | | Tissue enhanced |
BARX2 | BARX homeobox 2 | Transcription factors
| | | | | Tissue enhanced |
BASP1 | Brain abundant, membrane attached signal protein 1 | Cytoskeleton related proteins Plasma proteins Transporters
| | | | | Tissue enhanced |
BBOX1 | Butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1 | Enzymes
| | | | | Tissue enhanced |
BCAS1 | Breast carcinoma amplified sequence 1 | | | | | | Tissue enhanced |
BCL2L10 | BCL2-like 10 (apoptosis facilitator) | Mitochondrial proteins Predicted membrane proteins
| | | | | Tissue enhanced |
BCL2L14 | BCL2-like 14 (apoptosis facilitator) | | | | | | Tissue enhanced |
BHLHE22 | Basic helix-loop-helix family, member e22 | Transcription factors
| | | | | Tissue enhanced |
BICC1 | Bicaudal C homolog 1 (Drosophila) | Disease related genes
| | | | | Tissue enhanced |
BIRC7 | Baculoviral IAP repeat containing 7 | | | | | | Tissue enhanced |
BPIFB1 | BPI fold containing family B, member 1 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
BRIP1 | BRCA1 interacting protein C-terminal helicase 1 | Cancer-related genes Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
BTK | Bruton agammaglobulinemia tyrosine kinase | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
BVES | Blood vessel epicardial substance | Predicted membrane proteins
| | | | | Tissue enhanced |
C10orf115 | Chromosome 10 open reading frame 115 | | | | | | Tissue enhanced |
C12orf56 | Chromosome 12 open reading frame 56 | | | | | | Tissue enhanced |
C12orf60 | Chromosome 12 open reading frame 60 | | | | | | Tissue enhanced |
C14orf39 | Chromosome 14 open reading frame 39 | Plasma proteins
| | | | | Tissue enhanced |
C15orf48 | Chromosome 15 open reading frame 48 | | | | | | Tissue enhanced |
C16orf89 | Chromosome 16 open reading frame 89 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
C17orf53 | Chromosome 17 open reading frame 53 | | | | | | Tissue enhanced |
C17orf97 | Chromosome 17 open reading frame 97 | | | | | | Tissue enhanced |
C19orf57 | Chromosome 19 open reading frame 57 | | | | | | Tissue enhanced |
C19orf81 | Chromosome 19 open reading frame 81 | | | | | | Tissue enhanced |
C1orf106 | Chromosome 1 open reading frame 106 | | | | | | Tissue enhanced |
C1orf116 | Chromosome 1 open reading frame 116 | | | | | | Tissue enhanced |
C1orf170 | Chromosome 1 open reading frame 170 | | | | | | Tissue enhanced |
C1orf222 | Chromosome 1 open reading frame 222 | | | | | | Tissue enhanced |